Volume 70 Number 4 September 2003	back to contents

From the Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.

Address all correspondence to Thierry H. LeJemtel, M.D., Albert Einstein College of Medicine, 1300 Morris Park Avenue,
Forcheimer G44, Bronx, NY 10461; E-mail: lejemtel@aecom.yu.edu.

Based on a Grand Rounds presentation of the Division of Cardiology, Department of Medicine, Mount Sinai School of
Medicine, New York, NY on April 22, 2002, and updated in February 2003.

ABSTRACT

The rationale behind the use of angiotensin-converting enzyme (ACE) inhibitors has evolved considerably since their approval for the treatment of hypertension. The initial rationale behind their use for the treatment of chronic heart failure
was to duplicate with one agent the hemodynamic effects produced by the hydralazine-isosorbide dinitrate combination,
i.e., increasing cardiac output while reducing ventricular filling pressures. The observation that the acute hemodynamic
effects of ACE inhibitors did not predict long-term clinical benefits led to the search for mechanisms other than hemodynamic improvement. Attenuation or even reversal of left ventricular dilatation after myocardial infarction, which was first reported with ACE inhibition in an experimental model of myocardial infarction and subsequently in patients with recent myocardial infarction, provided a new rationale for the use of these inhibitors for chronic heart failure. However, this apparent prevention of left ventricular dilatation by ACE inhibitors is less apparent in patients with congestive heart failure due to left ventricular systolic dysfunction (decreased ejection fraction) than in patients with recent myocardial infarction. Furthermore, the unexpected finding that long-term ACE inhibition decreases the incidence of recurrent myocardial infarction in patients with coronary artery disease and an already reduced systolic function, suggested the hypothesis that vascular protection may provide most of the clinical benefits of ACE inhibitors. This hypothesis was successfully tested by demonstrating a lower incidence of cardiovascular events in high-risk vascular patients randomized to long-term ACE inhibition with ramipril. Accordingly, the current rationale behind the use of ACE inhibitors in patients with chronic heart failure is largely that of vascular protection.

KEY WORD

Angiotensin-converting enzyme inhibition, left ventricular remodeling, vascular protection, chronic heart failure.

MSSM Home

Back Issues | Indexes | Search | Journal Home